The pharmaceutical industry took another public relations hit when another brand of blood pressure medications was found to contain carcinogenic chemicals. The Food and Drug Administration announced that Aurobindo Pharma USA, Inc. will voluntarily recall Tablets, Valsartan HCTZ Tablets, and Valsartan Tablets.
The impurity detected, called N-nitrosodiethylamine (NDEA), is described by the FDA as a “substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen.”
Users have not reported any adverse effects as of today. The FDA posted a list of the recalled medications.
The FDA recommends that patients who are prescribed these medications continue taking them. The FDA feels the consequences of not taking them could be worse than the potential effects of ingesting carcinogenic chemicals. Because it seems, high blood pressure is worse than cancer (or something like that).
Blood pressure medications are under increasing scrutiny. Last month, Torrent Pharmaceuticals Limited recalled potassium tablets over NDEA traces. Two months ago, Mylan Pharmaceuticals recalled portions of amlodipine and valsartan for NDEA traces.
I’m getting high blood pressure just keeping up with how stressful “high blood pressure cures” currently are today.
Author: Jim Satney
PrepForThat’s Editor and lead writer for political, survival, and weather categories.
Please visit the CDC website for the most up-to-date COVID-19 information.
*As an Amazon Associate I earn from qualifying purchases